AstraZeneca Wins FDA Accelerated Nod for Camizestrant

AstraZeneca's camizestrant (Etcamah) now carries an FDA accelerated approval tied directly to a companion diagnostic, a pairing that sets immediate labeling, co-development, and post-marketing obligations for manufacturers operating in the HR-positive, HER2-negative metastatic breast cancer space. The September 4, 2026 decision covers camizestrant in combination with abemaciclib, palbociclib, or ribociclib for adults whose ESR1 mutation is detected during ongoing aromatase inhibitor and CDK4/6 inhibitor therapy.

The approval is inseparable from the Guardant360 CDx assay, which FDA simultaneously cleared as the companion diagnostic device for ESR1 mutation identification via circulating tumor DNA. For QA and regulatory leads, the ctDNA-based patient selection mechanism introduces a real-world complexity: therapy switching is triggered mid-treatment, not at initiation, requiring that labeling, prescribing workflows, and diagnostic ordering processes align precisely with the approved test and timing criteria.

Efficacy data derive from SERENA-6 (NCT04964934), a randomized, double-blind, placebo-controlled multicenter trial enrolling 315 patients. All participants had received at least six months of aromatase inhibitor plus CDK4/6 inhibitor therapy with no evidence of progression before randomization. Median progression-free survival reached 16 months in the camizestrant arm versus 9.2 months in the continued aromatase inhibitor arm (HR 0.44; 95% CI: 0.31, 0.60; p < 0.00001). Overall survival data were immature at the time of the PFS analysis.

The prescribing information carries a boxed warning for QTc interval prolongation-associated arrhythmia risk when camizestrant is used concomitantly with other QTc-prolonging agents, alongside warnings for bradycardia and embryo-fetal toxicity. The recommended dose is 75 mg orally once daily, with the CDK4/6 inhibitor continued at the same dose in use at the time of ESR1 mutation detection.

As an accelerated approval under Project Confirm, continued authorization remains contingent on verification of clinical benefit in a confirmatory trial. The review was conducted under Project Orbis, with concurrent submissions to the Australian TGA, Brazil's ANVISA, Health Canada, Singapore's HSA, and Switzerland's Swissmedic; reviews at those agencies may still be ongoing.

The confirmatory trial requirement under Project Confirm represents the next measurable checkpoint for AstraZeneca's regulatory timeline and for manufacturers tracking the camizestrant label's long-term standing.

Source: FDA Drugs Resources, Approved Drugs (What's New: Drugs RSS Feed) via fda.gov, September 4, 2026.